Publications by authors named "Brenda Homony"

Claim this Profile
S
Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1.
Sharon L Hillier, Linda-Gail Bekker, Sharon A Riddler, Craig W Hendrix, Sharlaa Badal-Faesen, Brenda Homony

J Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Exploratory Substudy of a Phase 2 Trial to Evaluate the Pharmacokinetic Effect of Once-Monthly Islatravir on Long-Acting Reversible Contraceptives.
Michelle Pham, Prachi Wickremasingha, Ryan Vargo, Munjal Patel, Katherine Nedrow, Brenda Homony

J Acquir Immune Defic Syndr· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use.
Alexander Mills, Laurie Myers, Casey Raudenbush, David A Vossen, Hedy Teppler, Brenda Homony

Pediatr Infect Dis J· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Sharon Nachman, Carmelita Alvero, Hedy Teppler, Brenda Homony, Anthony J Rodgers

Lancet HIV· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.
Pedro Cahn, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Winai Ratanasuwan, Brenda Homony

J Acquir Immune Defic Syndr· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Pedro Cahn, Richard Kaplan, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Brenda Homony

Lancet HIV· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.
Sharon Nachman, Carmelita Alvero, Edward P Acosta, Hedy Teppler, Brenda Homony

J Pediatric Infect Dis Soc· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.
Matthew L Rizk, Lihong Du, Chantelle Bennetto-Hood, Larissa Wenning, Hedy Teppler, Brenda Homony

J Clin Pharmacol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
Sharon Nachman, Nan Zheng, Edward P Acosta, Hedy Teppler, Brenda Homony

Clin Infect Dis· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis